Cookie Einstellungen
Diese Webseite verwendet ausschließlich notwendige Cookies, die für die Funktion erforderlich sind. Marketing- und Statistik-Cookies kommen nicht zum Einsatz. Weitere Informationen finden Sie in unserer Datenschutzerklärung.
 Notwendig   Details einblenden
      OK      
Bitte logge Dich ein, um diese Funktion zu nutzen!
      OK      
x
Impact News +++ Pfizer vs Moderna: Only One Pharma Giant Is a Winner In The Post-Covid Era (24/7 Wall St.) +++ MODERNA Aktie +4,59%

Foren & Soziale Netzwerke zur JOHNSON & JOHNSON Aktie

 >J&J Aktienkurs 
193.26 EUR    -1.4%    (TradegateBSX)
Ask: 193.02 EUR / 550 Stück
Bid: 192.86 EUR / 550 Stück
Tagesumsatz: 4630 Stück
Realtime Kurs von 7:30 bis 22 Uhr!
J&J Aktie über LYNX handeln
>J&J Performance
1 Woche: +1,0%
1 Monat: -7,2%
3 Monate: +2,0%
6 Monate: +19,3%
1 Jahr: +42,4%
laufendes Jahr: +10,8%
>JOHNSON & JOHNSON Aktie
Name:  JOHNSON & JOHNSON (J&J)
Land:  USA
Sektor:  Gesundheit
ISIN/ Wkn:  US4781601046 / 853260
Symbol/ Ticker:  JNJ (Frankfurt) / JNJ (NYSE)
Kürzel:  FRA:JNJ, ETR:JNJ, JNJ:GR, NYSE:JNJ
Index:  S&P500, DowJones
Webseite:  https://www.jnj.com/
Profil:  Johnson & Johnson is a holding company engaged in the research, development, manufacture, and sale of healthcare products worldwide. It operates through two primary segments: Innovative Medicine, focusing on pharmaceuticals in oncology, immunology, n..
>Volltext..
Marktkapitalisierung:  466614.6 Mio. EUR
Unternehmenswert:  495147.51 Mio. EUR
Umsatz:  82217.48 Mio. EUR
EBITDA:  28701.85 Mio. EUR
Nettogewinn:  17951.45 Mio. EUR
Gewinn je Aktie:  7.46 EUR
Schulden:  46915.23 Mio. EUR
Liquide Mittel:  18504.33 Mio. EUR
Operativer Cashflow:  19512.82 Mio. EUR
Bargeldquote:  0.38
Umsatzwachstum:  1.01%
Gewinnwachstum:  -9.67%
Dividende je Aktie:  4.46 EUR
Dividendenrendite:  2.29%
Dividendenschätzung:  2.33%
Div. Historie:  24.02.26 - 1.1031799€
25.11.25 - 1.12814€
>weitere anzeigen...
Insiderhandel:  -
Suchwörter:  JOHNSON & JOHNSON, J&J, JOHNSON&JOHNSON, JOHNSONJOHNSON, JNJ, JOHNSON AND JOHNSON, JOHNSON JOHNSON
Letzte Datenerhebung:  04.05.26
>J&J Kennzahlen
Aktien/ Unternehmen:
Aktien: 2407.22 Mio. St.
Frei handelbar: 99.86%
Rückkaufquote: 0.68%
Mitarbeiter: 140800
Umsatz/Mitarb.: 0.57 Mio. EUR
Analysten:
Analystenrating: Buy
Kursziel: 12.14%
Bewertung:
KGV: 26.28
KGV lG: 19.92
KUV: 5.8
KBV: 6.74
PEG-Ratio: -
EV/EBITDA: 17.25
Rentabilität:
Bruttomarge: 67.96%
Gewinnmarge: 21.83%
Operative Marge: 26.88%
Managementeffizenz:
Gesamtkaprendite: 10.66%
Eigenkaprendite: 26.42%
 >J&J Anleihen 
>J&J Peer Group
Gesundheit, Medizinprodukte & -technik/ Implantate/ Wundpflege, Neurologie/ psychische Behandlung/ Schlaganfälle, Onkologie/ Krebs- Behandlung, Herz-Kreislauf- Behandlung/ Kardiologie
 
23.04.26 - 17:54
Could we see another push higher for JNJ (TradingView)
 
While many believe there is a convincing top on JNJ at the 251 zone, which would indicate a much more meaningful correction below the 200 zone, evidence suggests that the 251 zone is more likely to be a lower degree, and that support in the 208 - 215 zone should hold. That said, from that support, Elliott Wave guidelines would suggest we look for another five-wave structure to the upside, in what would be a larger degree extended wave five. I base this on the following evidence: -Elliott wave guidelines suggest there should be bearish divergence between wave 3 and 5, and we should look for that divergence on a fractile basis to support the count. Keep in mind that the higher the timeframe of divergence, the more confirmation provided. That said, there is a lack of bearish weekly divergence between the December 15th 2025, weekly high at 215, and the March 2nd 2026, weekly high at 251, which would suggest that the 251 high is more likely not a wave 5 top, and instead a wave 3 top. Therefore, we would be lookin
20.04.26 - 15:48
Guggenheim: buy Johnson & Johnson (Sharewise)
 
Kursziel: 226.2596 €
16.04.26 - 15:48
Daiwa_Securities_Gro: buy Johnson & Johnson (Sharewise)
 
Kursziel: 208.1898 €
16.04.26 - 15:48
Argus: buy Johnson & Johnson (Sharewise)
 
Kursziel: 232.7325 €
15.04.26 - 15:48
The_Goldman_Sachs_Gr: buy Johnson & Johnson (Sharewise)
 
Kursziel: 233.42 €
15.04.26 - 15:48
Raymond_James: buy Johnson & Johnson (Sharewise)
 
Kursziel: 218.9904 €
15.04.26 - 15:48
Wells_Fargo___Compan: buy Johnson & Johnson (Sharewise)
 
Kursziel: 223.2344 €
14.04.26 - 18:42
Q1 - und Erhöhung Jahresprognose (Ariva)
 
https://de.marketscreener.com/boerse-nachrichten/johnson-johnson-hebt-prognose-fuer-2026-nach-uebertroffenen-erstquartalszahlen-an-ce7e50dfda80f227Johnson & Johnson hebt Prognose für 2026 nach übertroffenen Erstquartalszahlen an(MT Newswires) -- Johnson & Johnson (JNJ) hat am Dienstag seine Prognose für das Gesamtjahr angehoben, nachdem die Ergebnisse des ... -Tamakoschy
13.04.26 - 18:03
Earnings-Woche der Wahrheit: Banken, Netflix, ... (Ariva)
 
Dies ist ein automatisiert generierter Hinweis auf die neueste News zu "Johnson & Johnson Corp" aus der ARIVA.DE Redaktion.27 Schwergewichte legen Zahlen vor. Banken, Johnson & Johnson und Netflix müssen jetzt zeigen, wie sie mit Unsicherheit, Energiepreisen und nervösen Märkten umgehen. Darauf schaut die Wall Street ganz genau.Lesen Sie den ganzen Artikel: -ARIVA.DE
12.04.26 - 01:18
US4781601046 - Johnson & Johnson (Ariva)
 
Johnson & Johnson ist für mich zum Stand 11. April 2026 ein sehr hochwertiges, aber keineswegs billiges Qualitätsunternehmen. Die Aktie schloss am 10. April 2026 in den USA bei 238,46 US-Dollar, also auf dem letzten vorliegenden Schlusskurs vor Deinem Stichtag. Bezogen auf das bereinigte ... -MrTrillion3
10.04.26 - 18:03
Morgan_Stanley: buy Johnson & Johnson (Sharewise)
 
Kursziel: 228.3918 €
08.04.26 - 16:03
TD_Cowen: buy Johnson & Johnson (Sharewise)
 
Kursziel: 214.2 €
07.04.26 - 15:45
Citigroup_Inc_: buy Johnson & Johnson (Sharewise)
 
Kursziel: 247.1805 €
07.04.26 - 15:45
Guggenheim: buy Johnson & Johnson (Sharewise)
 
Kursziel: 211.6212 €
03.04.26 - 04:24
JNJ — Demand Zone Reaction + Pharma Pricing News + Dividend (TradingView)
 
✅ Chart Analysis 1. Demand Zone Rejection Price pulled back perfectly into a well‑defined demand zone — this is where buyers previously stepped in aggressively. The reaction confirms strong institutional demand. 2. Trendline Break + Retest A descending trendline was broken, and price successfully retested the trendline from above, turning previous resistance into new support. This is a classic continuation signal. 3. EMAs Supporting the Trend Price is trading above the 50‑day EMA, showing short‑term strength. The 200‑day EMA is trending upward, confirming long‑term bullish structure. 4. Volume Behavior During the dip into the demand zone, volume remained controlled — a sign of absorption instead of panic selling. 5. Stochastic Indicator Stochastics curled upward from lower levels, supporting a momentum continuation. ? Technical Bias: Bullish as long as price holds above the demand zone ✅ Trade Idea Entry zone: Inside the demand/support area Stop‑loss: Place the stop‑loss below the demand zone, or adjust
03.04.26 - 04:18
JNJ — Demand Zone Reaction + Pharma Pricing News + Upcoming Divi (TradingView)
 
✅ Chart Analysis 1. Demand Zone Rejection Price pulled back perfectly into a well‑defined demand zone — this is where buyers previously stepped in aggressively. The reaction confirms strong institutional demand. 2. Trendline Break + Retest A descending trendline was broken, and price successfully retested the trendline from above, turning previous resistance into new support. This is a classic continuation signal. 3. EMAs Supporting the Trend Price is trading above the 50‑day EMA, showing short‑term strength. The 200‑day EMA is trending upward, confirming long‑term bullish structure. 4. Volume Behavior During the dip into the demand zone, volume remained controlled — a sign of absorption instead of panic selling. 5. Stochastic Indicator Stochastics curled upward from lower levels, supporting a momentum continuation. ? Technical Bias: Bullish as long as price holds above the demand zone ✅ Trade Idea Entry zone: Inside the demand/support area Stop‑loss: Place the stop‑loss below the demand zone, or adjust
03.04.26 - 04:00
JNJ - Technical Rebound Aligning With Major Drug‑Pricing News (TradingView)
 
Based on the recent pharma agreements reported by Reuters — where 16 global drugmakers committed to lower U.S. prices in exchange for tariff exemptions — overall sector sentiment appears stable. Technically, price is reacting well within the demand zone, retesting structure and holding above key moving averages. This improves the probability of upside continuation but does not eliminate risk, especially given that FactCheck.org notes the long‑term impact of these agreements is still uncertain.
02.04.26 - 04:15
Ideal Strategy for JNJ (TradingView)
 
✅ ENTRY RANGE Anywhere near current price or on a dip to support. ✅ TARGET $255–$260 in 3–4 months (~5–8% gain) ✅ STOP-LOSS (optional) Below recent swing low $216–$220 (Very unlikely to hit unless big market shock) ✅ RISK LEVEL Low JNJ is one of the most stable stocks you can swing trade.
31.03.26 - 11:45
Johnson & Johnson (Ariva)
 
Die Aktie des Gesundheitskonzerns Johnson & Johnson steht nach mehreren neuen Unternehmensmeldungen erneut im Blickfeld. Eine weiter steigende Dividende und Fortschritte in der Medikamentenentwicklung könnten die Perspektiven für Anleger neu definieren.https://www.finanznachrichten.de/nachrichten-2026-03/68085524-johnson-johnson-aktie-neue-milliarden-phantasie-486.htm -Highländer49
30.03.26 - 19:33
Royal_Bank_of_Canada: buy Johnson & Johnson (Sharewise)
 
Kursziel: 221.4165 €
>Behalte deine Investments mit realtime Kursen & News im Blick. Finde neue spannende Aktien! Registriere Dich und werde Mitglied!
Zitat des Tages: Die Frauen bewundern einen Mann wegen seiner Stärke, aber sie lieben ihn wegen seiner Schwächen. - Beatrice Brown
>Aktien | >Anleihen | >ETFs | >Fonds | >Branchen | >Länder | >Themen | >Redaktionen
Partner:    >TradegateBSX Börse | >Dukascopy | >TradingView | >Boersentreff- Partner

Börsentreff auf Facebook | Börsentreff auf X | Börsentreff auf Instagram

Copyright @ Boersentreff.de - Die Märkte im Blick!